These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2899491)

  • 1. Use of histamine2-receptor blocking agents and sucralfate in a health maintenance organization following continued clinical pharmacist intervention.
    Mead RA; McGhan WF
    Drug Intell Clin Pharm; 1988 Jun; 22(6):466-9. PubMed ID: 2899491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-use review program for concurrent histamine H2-receptor antagonist-sucralfate therapy.
    Kane MP; Briceland LL; Garris RE; Favreau BN
    Am J Hosp Pharm; 1990 Sep; 47(9):2007-10. PubMed ID: 1977317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiulcer prescribing program in a state correctional system.
    Keith MR; Cason DM; Helling DK
    Ann Pharmacother; 1994 Jun; 28(6):792-6. PubMed ID: 7919571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving antiulcer agent prescribing in a health maintenance organization.
    Raisch DW; Bootman JL; Larson LN; McGhan WF
    Am J Hosp Pharm; 1990 Aug; 47(8):1766-73. PubMed ID: 2389782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Shifting physician prescribing to a preferred histamine-2-receptor antagonist. Effects of a multifactorial intervention in a mixed-model health maintenance organization.
    Brufsky JW; Ross-Degnan D; Calabrese D; Gao X; Soumerai SB
    Med Care; 1998 Mar; 36(3):321-32. PubMed ID: 9520957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparative evaluation of the efficacy of sucralfate and H2-histamine blockaders in treating peptic ulcer].
    Ivashkin VT; Tkachenko EI; Grinevich VB; Sultanov VK; Inozemtsev SA
    Ter Arkh; 1989; 61(8):59-62. PubMed ID: 2573963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impacting cost and appropriateness of stress ulcer prophylaxis at a university medical center.
    Erstad BL; Camamo JM; Miller MJ; Webber AM; Fortune J
    Crit Care Med; 1997 Oct; 25(10):1678-84. PubMed ID: 9377882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National survey of stress ulcer prophylaxis.
    Lam NP; Lê PD; Crawford SY; Patel S
    Crit Care Med; 1999 Jan; 27(1):98-103. PubMed ID: 9934901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists.
    Andrade SE; Gurwitz JH; Fish LS
    Med Care; 1999 Apr; 37(4):424-30. PubMed ID: 10213023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses.
    Cook DJ; Reeve BK; Guyatt GH; Heyland DK; Griffith LE; Buckingham L; Tryba M
    JAMA; 1996 Jan 24-31; 275(4):308-14. PubMed ID: 8544272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group.
    Cook D; Guyatt G; Marshall J; Leasa D; Fuller H; Hall R; Peters S; Rutledge F; Griffith L; McLellan A; Wood G; Kirby A
    N Engl J Med; 1998 Mar; 338(12):791-7. PubMed ID: 9504939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination sucralfate and histamine2-antagonist therapy.
    Gales MA; Steadman BK
    Ann Pharmacother; 1994 May; 28(5):597-600. PubMed ID: 7915150
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of pharmacist interventions on the inappropriate use of acid-suppression therapy.
    Hughes GJ; Belgeri MT; Perry HM
    Consult Pharm; 2011 Jul; 26(7):485-90. PubMed ID: 21729849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sucralfate versus antacids or H2-antagonists for stress ulcer prophylaxis: a meta-analysis on efficacy and pneumonia rate.
    Tryba M
    Crit Care Med; 1991 Jul; 19(7):942-9. PubMed ID: 1675976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duodenal ulcer. Who should have long-term maintenance therapy?
    Zuckerman G
    Postgrad Med; 1987 Oct; 82(5):52-3, 57-8, 60. PubMed ID: 2890147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic aspects and formulary considerations related to histamine2-receptor antagonists.
    Souney PF; Stoukides CA
    DICP; 1989 Oct; 23(10 Suppl):S29-35. PubMed ID: 2573207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic bleeding secondary to an unresectable duodenal adenocarcinoma controlled with sucralfate and famotidine.
    Gonzales-Rosales F; Walsh D; Burkons L; Burkons J; Horvitz HR
    Palliat Med; 1998 May; 12(3):205-6. PubMed ID: 9743840
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence of infectious complications associated with the use of histamine2-receptor antagonists in critically ill trauma patients.
    O'Keefe GE; Gentilello LM; Maier RV
    Ann Surg; 1998 Jan; 227(1):120-5. PubMed ID: 9445119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sucralfate maintenance therapy in duodenal ulcer disease. A review.
    Bolin TD
    Am J Med; 1989 Jun; 86(6A):148-51. PubMed ID: 2567571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of direct pharmacist intervention on conversion from parenteral to oral histamine H2-receptor antagonist therapy.
    Kirking DM; Svinte MK; Berardi RR; Cornish LA; Chaffee BW; Ryan ML
    DICP; 1991 Jan; 25(1):80-4. PubMed ID: 1672572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.